Emergency use authorization indicated for those who have been exposed to SARS-CoV-2 and have an immunocompromising condition
FDA Approves Third COVID-19 Antibody Treatment for Emergency Use
Study found that patients who received sotrovimab showed an 85 percent reduction in their risk for hospitalization or death versus placebo
Combination Monoclonal Antibody Treatment Authorized for COVID-19
EUA issued for combination of bamlanivimab and etesevimab in patients with mild-to-moderate COVID-19 at high risk for disease progression